No. | Experimental reported Activity, (Pa)* | Predicted theoretical biological activity, (Pa)* | Related reference |
1 | Inhibitor of the glycolytic enzyme enolase 2 | Stroke treatment (0.761); Neuroprotector (0.744); Acute neurologic disorders treatment (0.663); Antineoplastic (sarcoma) (0.646); Antinephrotoxic (0.587); Antiseborrheic (0.578) | (15, 16, 21) |
2 | Not reported | Stroke treatment (0.979); Antiviral (0.897); Antiviral (HIV) (0.887) Antinephrotoxic (0.701); Bone formation stimulant (0.653) | (29, 31) |
3 | Not reported | Antibiotic Glycopeptide-like (0.984); Stroke treatment (0.538) Antischistosomal (0.510) | (21) |
4 | Not reported | Antiarthritic (0.963); Anti-inflammatory (0.942); Acute neurologic disorders treatment (0.765); Bone formation stimulant (0.615) Antinephrotoxic (0.608); Stroke treatment (0.567) Leukopoiesis stimulant (0.542); Bone diseases treatment (0.539) | (30) |
5 | Not reported | Bone formation stimulant (0.813); Bone diseases treatment (0.803) Acute neurologic disorders treatment (0.650); Antinephrotoxic (0.604) Antiosteoporotic (0.560); Leukopoiesis stimulant (0.526) | (31) |
6 | Not reported | Acute neurologic disorders treatment (0.834); Stroke treatment (0.583) Bone formation stimulant (0.574); Bone diseases treatment (0.536) Anesthetic general (0.517); Leukopoiesis stimulant (0.506) | (31) |
7 | Not reported | Acetylesterase inhibitor (0.618); Anticonvulsant (0.533) | (19, 20) |
8 | Not reported | Anticonvulsant (0.664); Acetylesterase inhibitor (0.637); Acute neurologic disorders treatment (0.513) | (19, 20) |
9 | Not reported | Acetylesterase inhibitor (0.687); Myasthenia Gravis treatment (0.562) | (19, 20) |
10 | Not reported | Cognition disorders treatment (0.765) | (19, 20) |
11 | Not reported | Calcium regulator (0.548); Antihypertensive (0.503) | (32) |
12 | Not reported | Acute neurologic disorders treatment (0.852); Stroke treatment (0.582) Bone diseases treatment (0.580); Bone formation stimulant (0.531) | (33) |
17a | Not reported | Acetylesterase inhibitor (0.611); Insulinotropin antagonist (0.568) | Present study |
17b | Not reported | Spasmolytic, urinary (0.954) | Present study |
17c | Not reported | Acetylesterase inhibitor (0.572); Immunostimulant (0.522) | Present study |
17d | Not reported | Acetylesterase inhibitor (0.618); Immunostimulant (0.544) | Present study |
17e | Not reported | Acetylesterase inhibitor (0.618); Immunostimulant (0.544) | Present study |
17f | Not reported | Purinergic P2Y2 antagonist (0.512) | Present study |
17g | Not reported | No activities with Pa > 0.5 | Present study |
17h | Not reported | General pump inhibitor (0.600) | Present study |